DUBLIN, May 28, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/xlcslc/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies. Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2020. Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines. Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics. Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2014-2024. Profiles of 313 companies involved in developing technologies for personalized medicines, along with 567 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 74 tables and 26 figures. Key Topics Covered:
Part I: Scientific & Commercial Aspects Executive Summary 1. Basic Aspects 2. Molecular Diagnostics in Personalized Medicine 3. Pharmacogenetics 4. Pharmacogenomics 5. Role of Pharmacoproteomics 6. Role of Metabolomics in Personalized Medicine 7. Personalized Biological Therapies 8. Personalized Non-pharmacological Therapies 9. Personalized Medicine in Major Therapeutic Areas 10. Personalized Therapy of Cancer 11. Development of Personalized Medicine 12. Ethical, Legal and Regulatory Aspects of Personalized Medicine 13. Commercial Aspects of Personalized Medicine 14. References Part II: Companies 15. Companies Involved in Developing Personalized Medicine
For more information visit http://www.researchandmarkets.com/research/xlcslc/personalized Source: Jain PharmaBiotech
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Advertisement
Research and Markets (http://www.researchandmarkets.com/research/xlcslc/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies. Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2020. Several players are involved in the development of personalized therapy. Pharmaceutical and biotechnology companies have taken a leading role in this venture in keeping with their future role as healthcare enterprises rather than mere developers of technologies and manufacturers of medicines. Ethical issues are involved in the development of personalized medicine mainly in the area of genetic testing. These along with social issues and consideration of race in the development of personalized medicine are discussed. Regulatory issues are discussed mainly with reference to the FDA guidelines on pharmacogenomics. Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2014-2024. Profiles of 313 companies involved in developing technologies for personalized medicines, along with 567 collaborations are included in the part II of the report. Finally the bibliography contains over 750 selected publications cited in the report.The report is supplemented by 74 tables and 26 figures. Key Topics Covered:
Advertisement
Part I: Scientific & Commercial Aspects Executive Summary 1. Basic Aspects 2. Molecular Diagnostics in Personalized Medicine 3. Pharmacogenetics 4. Pharmacogenomics 5. Role of Pharmacoproteomics 6. Role of Metabolomics in Personalized Medicine 7. Personalized Biological Therapies 8. Personalized Non-pharmacological Therapies 9. Personalized Medicine in Major Therapeutic Areas 10. Personalized Therapy of Cancer 11. Development of Personalized Medicine 12. Ethical, Legal and Regulatory Aspects of Personalized Medicine 13. Commercial Aspects of Personalized Medicine 14. References Part II: Companies 15. Companies Involved in Developing Personalized Medicine
For more information visit http://www.researchandmarkets.com/research/xlcslc/personalized Source: Jain PharmaBiotech
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
